ImmuPharma PLC Company Profile (LON:IMM)

About ImmuPharma PLC (LON:IMM)

ImmuPharma PLC logoImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: LON:IMM
  • CUSIP: N/A
  • Web:
  • Market Cap: £75.54 million
  • Outstanding Shares: 132,522,000
Average Prices:
  • 50 Day Moving Avg: GBX 53.24
  • 200 Day Moving Avg: GBX 53.83
  • 52 Week Range: GBX 31.44 - GBX 70.32
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $164,783.00
  • Price / Sales: 458.41
  • Book Value: GBX 0.04 per share
  • Price / Book: 14.25
  • EBIDTA: ($6,470,000.00)
  • Net Margins: -977.88%
  • Return on Equity: -53.96%
  • Return on Assets: -45.00%
  • Average Volume: 204,432 shs.
Frequently Asked Questions for ImmuPharma PLC (LON:IMM)

What is ImmuPharma PLC's stock symbol?

ImmuPharma PLC trades on the London Stock Exchange (LON) under the ticker symbol "IMM."

When will ImmuPharma PLC make its next earnings announcement?

ImmuPharma PLC is scheduled to release their next quarterly earnings announcement on Thursday, September, 28th 2017. View Earnings Estimates for ImmuPharma PLC.

Where is ImmuPharma PLC's stock going? Where will ImmuPharma PLC's stock price be in 2017?

2 brokerages have issued 12-month price objectives for ImmuPharma PLC's shares. Their forecasts range from GBX 100 to GBX 181. On average, they expect ImmuPharma PLC's stock price to reach GBX 140.50 in the next year. View Analyst Ratings for ImmuPharma PLC.

Who are some of ImmuPharma PLC's key competitors?

Who are ImmuPharma PLC's key executives?

ImmuPharma PLC's management team includes the folowing people:

  • Robert Henri Zimmer M.D., Ph.D., President, Chief Scientific Officer, Director
  • Dimitri F. Dimitriou, Chief Executive Officer, Director
  • Tracy Weimar, Vice President - Operations and Finance, Company Secretary
  • Timothy McCarthy, Non-Executive Chairman of the Board
  • Stephane Robert Mery, Non-Executive Director

How do I buy ImmuPharma PLC stock?

Shares of ImmuPharma PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ImmuPharma PLC's stock price today?

One share of ImmuPharma PLC stock can currently be purchased for approximately GBX 57.

MarketBeat Community Rating for ImmuPharma PLC (LON IMM)
Community Ranking:  4.1 out of 5 (   )
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  23 (Vote Underperform)
Total Votes:  124
MarketBeat's community ratings are surveys of what our community members think about ImmuPharma PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ImmuPharma PLC (LON:IMM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 140.50

Analysts' Ratings History for ImmuPharma PLC (LON:IMM)
DateFirmActionRatingPrice TargetDetails
6/30/2017Northland SecuritiesBoost Price TargetBuyGBX 171 -> GBX 181View Rating Details
4/20/2017Panmure GordonReiterated RatingBuyGBX 100View Rating Details
7/20/2016Northland Capital PartnersInitiated CoverageBuyGBX 171View Rating Details
(Data available from 7/23/2015 forward)


Earnings History for ImmuPharma PLC (LON:IMM)
Earnings by Quarter for ImmuPharma PLC (LON:IMM)
Earnings History by Quarter for ImmuPharma PLC (LON IMM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
9/28/2017N/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ImmuPharma PLC (LON:IMM)
Current Year EPS Consensus Estimate: $-4.26 EPS


Dividend History for ImmuPharma PLC (LON:IMM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for ImmuPharma PLC (LON:IMM)
No insider trades for this company have been tracked by


Headline Trends for ImmuPharma PLC (LON:IMM)
Latest Headlines for ImmuPharma PLC (LON:IMM)
DateHeadline logoImmuPharma PLC (LON:IMM) PT Raised to GBX 181 at Northland Securities - July 1 at 12:36 PM logoImmuPharma Recruits And Doses 200 Patients In Phase III Lupuzor Trial - June 30 at 7:58 PM logoIMM. Reading back t- - June 24 at 11:18 PM logoNorthland Securities Reiterates "Buy" Rating for ImmuPharma PLC (IMM) - June 7 at 9:44 PM logoImmuPharma 2016 Loss Widens As It Progresses Lupus Phase III Trial - June 2 at 8:09 AM logoImmuPharma PLC (IMM) Given Buy Rating at Northland Securities - June 1 at 6:04 AM logoImmuPharma PLC's (IMM) "Buy" Rating Reiterated at Northland Securities - May 18 at 7:47 PM logoImmuPharma PLC's (IMM) Buy Rating Reaffirmed at Panmure Gordon - April 20 at 7:37 PM logoImmuPharma PLC (IMM) Stock Rating Reaffirmed by Northland Securities - March 24 at 6:37 AM logoImmuPharma PLC (IMM) Receives Buy Rating from Northland Securities - March 20 at 6:42 AM logoImmuPharma PLC (IMM) Rating Reiterated by Northland Securities - March 13 at 6:54 AM logoUPDATE: ImmuPharma Raises GBP4.1 Million, Seeks Partners For Lupuzor (ALLISS) - March 11 at 12:07 AM logoPeter Thiel's New Zealand citizenship stokes political debate - February 10 at 4:51 AM logoBRIEF-ImmuPharma says update on lupuzor pivotal phase iii study - January 25 at 7:18 PM logoImmuPharma PLC: Update on Lupuzor™ Pivotal Phase III Study Full Analysis of Patient Recruitment - January 25 at 7:18 PM logoUpdate on Lupuzor Pivotal Phase III Study - London South East (registration) (blog) - December 23 at 11:10 PM logoLegal & General Buys 3.4% Stake In Junior Drug Firm ImmuPharma (ALLISS) - November 9 at 6:56 AM logoClose of Accelerated Bookbuild - October 22 at 5:18 PM logoImmuPharma Investor To Place Shares, Company To Raise GBP800,000 (ALLISS) - October 21 at 5:40 PM


Social activity is not available for this stock.


ImmuPharma PLC (IMM) Chart for Sunday, July, 23, 2017

This page was last updated on 7/23/2017 by Staff